MYC and acute myeloid leukemia: To determine whether WBC100‐mediated antitumor activity is superior to known c‐Myc transcription inhibitors and chemotherapeutic agents, we compared the antitumor activities of WBC100 with the c‐Myc transcription inhibitor (+)‐JQ1 (BET inhibitor)[48] and standard‐of‐care chemotherapeutic agent idarubicin (IDA) against human refractory AML using orthotopic NSG mouse model with MOLM‐13‐luciferase cells.